Sutro Biopharma has received $26m in a Series D financing, which will be used for the expansion of its proprietary immuno-oncology product pipeline.
The company is currently using its cell-free protein synthesis technology to develop new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies.
The closing of the financing was led by the company's existing investors Alta Partners, Amgen Ventures, Celgene, Lilly Ventures, Skyline Ventures and SV Life Sciences.
Since its establishment in 2003, the company has raised more than $90m.
Sutro Biopharma chief executive officer William Newell said the successful financing is a tremendous validation of the company's emerging product pipeline together with its broad technology platform.
"We will continue to advance candidates that leverage the immune system's natural ability to fight cancer, with the goal of establishing next generation immuno-oncology products that will transform cancer therapy for physicians and patients," Newell said.
The company is currently developing a new generation of antibody drug conjugate therapeutics and bifunctional antibody-based therapeutics for targeted cancer therapies.
The therapies are expected to extend the clinical impact of current oncology therapeutic approaches and are beyond what can be envisioned with current, cell-based expression technologies.
